Back to Search Start Over

319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC.

Authors :
Yang, J.C-H.
Liu, G.
Lu, S.
He, J.
Burotto, M.
Vincent, S.
Yin, J.
Ma, X.
Popat, S.
Source :
Annals of Oncology. Nov2022 Suppl 9, Vol. 33, pS1564-S1564. 1p.
Publication Year :
2022

Subjects

Subjects :
*CRIZOTINIB
*NON-small-cell lung carcinoma

Details

Language :
English
ISSN :
09237534
Volume :
33
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
160398256
Full Text :
https://doi.org/10.1016/j.annonc.2022.10.356
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details